AQST — AQUESTIVE THERAPEUTICS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
About AQUESTIVE THERAPEUTICS INC (AQST)
AQUESTIVE THERAPEUTICS INC (AQST) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $10M. Across recent filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AQST
How many top investors track AQST
A small number of top investors own this.
AQST Ownership Composition
How AQUESTIVE THERAPEUTICS INC is held across tracked investor types, based on reported 13F positions.
- Other78.7%
- Hedge Funds21.3%
Tracked investors reporting AQST
- Izzy EnglanderMar 31, 2026Millennium ManagementShares25.9KValue$107.3K% Portfolio0.00%
- Ken GriffinMar 31, 2026Citadel AdvisorsShares1MValue$4.2M% Portfolio0.00%
- Steve CohenMar 31, 2026Point72 Asset ManagementShares283.7KValue$1.2M% Portfolio0.00%
Recent activity
- $9.9MFeb 17, 2026
- $107.3KMay 15, 2026
- New$4.2MMay 15, 2026
- New$1.2MMay 15, 2026
- New$5.8MNov 14, 2025
Frequently asked questions
- How many institutional investors hold AQST?
- 3 tracked institutional investors disclosed a position in AQST (AQUESTIVE THERAPEUTICS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AQST?
- Izzy Englander, Millennium Management, holds the largest disclosed position in AQST, valued at $10M.
- Did institutional ownership of AQST increase or decrease?
- Across recent 13F filings, tracked investors recorded 5 new positions, 0 increased, 0 reduced, and 0 fully exited AQST.
- Where does this AQST ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.